

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Richard L. Franklin	:	Group Art Unit: 1648
	:	
Application No.: 10/750,184	:	Examiner: Zachariah Lucas
	:	
Filed: December 31, 2003	:	Attorney Docket No.: ARC-1001USCON1
	:	
For: REMOVING DENTAL PLAQUE	:	Confirmation No.: 4994
WITH KRILL ENZYMES	:	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(c)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached Substitute Form PTO 1449. A fee of \$180 is paid herewith to ensure consideration of this Information Disclosure Statement.

All of the references cited on the attached Substitute PTO 1449 were previously cited in the parent application (U.S. Patent Application No. 09/549,642, now abandoned), except for three U.S. Patents which are patents that issued on U.S. patent applications to which the present application claims benefit. Copies of the non-U.S. patent references can be found in the parent application.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Substitute PTO 1449 form.

This submission does not represent that a search has been made (37 C.F.R. §1.97(g)) or that no better art exists and does not constitute an admission that each or all of the listed documents are material (37 C.F.R. §1.97(h)) or constitute "prior art". The filing of this information disclosure statement shall not be construed as an admission against interest in any matter. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

If the Examiner applies any document as prior art against any claims in the application and Applicant determined that the cited document does not constitute "prior art" under United

States law, Applicants reserve the right to present to the Patent Office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should one the document be applied against the claims of the present application.

Respectfully submitted,

Date: September 6, 2006



Kevin J. Dunleavy
Registration No. 72,024

Customer No. 21,302
KNOBLE YOSHIDA & DUNLEAVY, LLC
Eight Penn Center, Suite 1350
1628 John F. Kennedy Blvd.
Philadelphia, PA 19103
Telephone: (215) 599-0600
Facsimile: (215) 599-0601
Email: kjdunleavy@patentwise.com

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10750184	
	Filing Date		2003-12-31	
	First Named Inventor	Richard L. Franklin		
	Art Unit	1648		
	Examiner Name	Zachariah Lucas		
	Attorney Docket Number	ARC-1001USCON1		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5945102		1999-08-31	de Faire et al.	
	2	5958406		1999-09-28	de Faire et al.	
	3	6030612		2000-02-29	de Faire et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20060134641		2006-06-22	Franklin	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0170115	EP		1985-07-09	Kao Corporation		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10750184
Filing Date		2003-12-31
First Named Inventor	Richard L. Franklin	
Art Unit	1648	
Examiner Name	Zachariah Lucas	
Attorney Docket Number	ARC-1001USCON1	

2	61068419	JP		1986-04-08	Kao Corporation		<input type="checkbox"/>
3	9319732	WO		1993-10-14	Unilever PLC		<input type="checkbox"/>
4	9324142	WO		1993-12-09	Phairson Medical AB		<input type="checkbox"/>
5	9419005	WO		1994-09-01	Albert Scheller		<input type="checkbox"/>
6	9507686	WO		1995-03-23	Unilever PLC		<input type="checkbox"/>
7	9507688	WO		1995-03-23	Unilever PLC		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Athie, Medicina (Mex) 45(961):145-150 (1965) [Spanish].	<input type="checkbox"/>
	2	Zhailiev DS, Khirurgiia (Mosk), (1):67-70 (1984) [Russian].	<input type="checkbox"/>
	3	Szeghy, Klin Monatshl Augenheilkd, 153(6):827-830 (1968) [German].	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10750184
Filing Date		2003-12-31
First Named Inventor	Richard L. Franklin	
Art Unit	1648	
Examiner Name	Zachariah Lucas	
Attorney Docket Number	ARC-1001USCON1	

4	Rathgeber WF, S. Afr. Med. J., (45(7):181-183 (1971) [English].	<input type="checkbox"/>
5	Coblentz, J. Am. Geriatr Soc., 16(9):1039-1046 (1968) [English].	<input type="checkbox"/>
6	V.N. Glozman, (10):57-59 (1990) [Russian].	<input type="checkbox"/>
7	T.K. Chuchnova, (10):52-55 (1990) [Russian].	<input type="checkbox"/>
8	Grant et al., Amino Acid Sequence of a Collagneolytic Protease from the Hepatopancreas of the Fiddler Crab, UCA Pugilator, Biochemistry, 19:4653-4659 (1980).	<input type="checkbox"/>
9	Grant and Eisen, Substrate Specificity of the Collagenolytic Serine Protease from Uca Pugilator: Studies with Noncollagegenous Substrates, Biochemistry, 19:6089-6095 (1980).	<input type="checkbox"/>
10	Grant et al., Collagenolytic Protease from Fiddler Crab (Uca Pugilator), Methods in Enzymology, 80:722-734 (1980).	<input type="checkbox"/>
11	Welgus et al., Substrate Specificity of the Collagenolytic Serine Protease from Uca Pugilator: Studies with Collagenous Substrates, Biochemistry, 21:5183-5189 (1982).	<input type="checkbox"/>
12	Grant et al., A Collagenolytic Serine Protease with Trypsin-Like Specificity from the Fiddler Crab Uca Pugilator, Biochemistry, 22:354-358 (1983).	<input type="checkbox"/>
13	Welgus and Grant, Degradation of Collagen Substrates by a Trypsin-Like Serine Protease from the Fiddler Crab Uca Pugilator, Biochemistry, 22:2228-2233 (1983).	<input type="checkbox"/>
14	Al-Mohanna et al., Mitotic E- and Secretory F-Cells in the Hepatopancreas of the Shrimp Penaeus Semisulcatus (Crustacea: Decapoda), J. Mar. Biol. Ass. U.K., 65:901-910 (1985).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10750184
Filing Date		2003-12-31
First Named Inventor	Richard L. Franklin	
Art Unit		1648
Examiner Name	Zachariah Lucas	
Attorney Docket Number		ARC-1001USCON1

15	Lipman and Pearson, Rapid and Sensitive Protein Similarity Searches, Science, 227:1435-1441 (Mar. 22, 1985).	<input type="checkbox"/>
16	Gudmundsodottir et al., Isolation and Characterization of cDNAs from Atlantic Cod Encoding Two Different Forms of Trypsinogen, Eur. J. Biochem., 217, 1091-1097 (1993).	<input type="checkbox"/>
17	Lu et al., The Midgut Trypsins of Shrimp (Penaeus Monodon), Biol. Chem. Hoppe-Seyler, 371:851-859 (Sep. 1990).	<input type="checkbox"/>
18	Turkiewicz et al., Collagenolytic Serine Proteinase from Euphausia Superba Dana (Antarctic Krill), Comp. Biochem. Physiol., 99B:359-371 (1991).	<input type="checkbox"/>
19	Tsai et al., The Midgut Chymotrypsins of Shrimps (Penaeus Monodon, Penaeus Japonicus and Penaeus Penicillatus) Biochimica et Biophysica Acta, 1080:59-67 (1991).	<input type="checkbox"/>
20	Wormhoudt et al., Purification, Biochemical Characterization and N-Terminal Sequence of a Serine-Protease with Chymotryptic and Collagenolytic Activities in a Tropical Shrimp, Penaeus Vannamei (Crustacea, Decapoda), Comp. Biochem. Physiol., 103B(3):675-680 (1992).	<input type="checkbox"/>
21	Sellos and Wormhoudt, Molecular Cloning of a cDNA that Encodes a Serine Protease with Chymotryptic and Collagenolytic Activities in the Hepatopancreas of the Shrimp Penaeus Vanameii (Crustacea, Decapoda), FEBS, 309 (3):219-224 (Sep. 1992).	<input type="checkbox"/>
22	Klimova et al., The Isolation and Properties of Collagenolytic Proteases from Crab Hepatopancreas, Biochemical and Biophysical Research Communications, 166(3):1411-1420 (Feb. 1990).	<input type="checkbox"/>
23	Tsu et al., The Substrate Specificity of Uca Pugilator Collagenolytic Serine Protease 1 Correlates with the Bovine Type I Collagen Cleavage Sites, The Journal of Biochemical Chemistry, 269(30):19565-19572 (1994).	<input type="checkbox"/>
24	B. Johansson et al., Purification and Identification of Carboxy-Peptidase A and B from Antarctic Krill (Euphausia Superba), Biol. Chem. Hoppe Sryler, 367:366, Abstract 06.03.56 (1986).	<input type="checkbox"/>
25	A. Bucht et al., Immunological Characterization of Three Highly Purified Trypsin-Like Enzymes from Antarctic Krill (Euphausia Superba), Biol. Chem. Hoppe Sryler, 367:366, Abstract 06.03.55 (1986).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10750184
Filing Date		2003-12-31
First Named Inventor	Richard L. Franklin	
Art Unit		1648
Examiner Name	Zachariah Lucas	
Attorney Docket Number		ARC-1001USCON1

26	Turkiewicz et al., Purification and Characterization of a Proteinase from Euphausia Superba Dana (Antarctic Krill), Acta Biochimica Polonica, 33(2):87-89 (1986).	<input type="checkbox"/>
27	Chen et al., Purification and Properties of Trypsin-Like Enzymes and a Carboxypeptidase A From Euphausia Superba, Journal of Food Biochemistry, 2:349-366 (1978).	<input type="checkbox"/>
28	Kimoto et al., Purification and Characterization of Serine Proteinases from Euphasia Superba, Agric. Biol. Chem., 47 (3):529-534 (1983).	<input type="checkbox"/>
29	Kimoto et al., Purification and Characterization of Chymotrypsin-Like Proteinase from Euphausia Superba, Agric. Biol. Chem., 49(6):1599-1603 (1985).	<input type="checkbox"/>
30	Knut Kr. Osnes et al., On the Purification and Characterization of Three Anoinic, Serine-Type Peptide Hydrolases from Antarctic Krill, Euphausia Superba, Comp. Biochem. Physiol., 82B(4):607-619 (1995).	<input type="checkbox"/>
31	Knut Kr. Osnes et al., On the Purification and Characterization of Exopeptidases from Antarctic Krill, Euphausia Superba, Comp. Biochem. Physiol., 83B(2):445-458 (1986).	<input type="checkbox"/>
32	Knut Kr. Osnes et al., Hydrolysis of Proteins by Peptide Hydrolases of Antarctic Krill, Euphausia Superba, Comp. Biochem. Physiol., 83B(4):801-805, (1986).	<input type="checkbox"/>
33	Knut Kr. Osnes et al., Peptide Hydrolases of Antarctic Krill, Euphausia Superba, Comp. Biochem. Physiol, 82B (4):599-606, (1985).	<input type="checkbox"/>
34	Olav Seather et al., Proteolysis Post Mortem in North Atlantic Krill, Comp. Biochem. Physical, 88B(1):165-176 (1987).	<input type="checkbox"/>
35	Dialog Search relating to enzyme-based therapeutics.	<input type="checkbox"/>
36	J. Melrose et al., Evaluation of Digestive Proteinases from the Antarctic Krill Euphausia Superba, as Potential Chemonucleolytic Agents, Arch Orthop Trauma Surg., 114:145-152 (1995).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10750184
Filing Date		2003-12-31
First Named Inventor	Richard L. Franklin	
Art Unit		1648
Examiner Name	Zachariah Lucas	
Attorney Docket Number		ARC-1001USCON1

37	Y. Sakharov, Potent Debriding Ability of Collagenolytic Protease Isolated from the Hepatopancreas of the King Crab Paralithodes Camtschatica, Arch Dermatol Res., 285:32-35 (1993).	<input type="checkbox"/>
38	Arthur Z. Eisen, A Collagenolytic Protease from the Hepatopancreas of the Fiddler Crab, UCA Pugilator, Purification and Properties, Biochemistry, 12(9):1814-1822 (1973).	<input type="checkbox"/>
39	Asuncion Olalla et la., Purification and Properties of Three Proteases from the Larvae of the Brine Shrimp Artemia Salina, Biochimica et Biophysica Acta, 523:181-190 (1978).	<input type="checkbox"/>
40	Spindler et al., Partial Characterization of Chitin Degrading Enzymes from Two Euphausiids, Euphausia Superba, and Meganyctiphanes Norvegica, Polar Biology, 9:115-122 (1988).	<input type="checkbox"/>
41	Karlstam and Ljunglof, Detection and Partial Purification of a Hyaluronic Acid-Degrading Enzyme from Antarctic Krill (Euphausia Superba,), Biol. Chem. Hoppe Seyler, 367:339 (1986).	<input type="checkbox"/>
42	Kimoto et al., Acid Proteinases from Antarctic Krill, Euphausia Superba: Partial Purification and Some Properties, Journal of Food Science, 46:1881-1884 (1981).	<input type="checkbox"/>
43	Kraft and Falkenberg, Biol. Chem. Hoppe Seyler, 353:1540-1541 (1972).	<input type="checkbox"/>
44	Anheller et al., Biochemical and Biological Profile of a New Enzyme Preparation from Antarctic Krill (E. Superba) Suitable for Debridemen of Ulcerative Lesions, Archives of Dermatology Research, 281:105-110 (1989).	<input type="checkbox"/>
45	Sakharov et al., Purification and Characterization of Two Serine Collagenolytic Proteases from Crab Paralithodes Camtschatica, Comp. Biochem. Physiol., 108B:561-568 (1994).	<input type="checkbox"/>
46	Gates et al., Isolation of Comparative Properties of Shrimp Trypsin, Shrimp Trypsin, 8(11):4483-4489 (1969).	<input type="checkbox"/>
47	Dialog Search relating to cysteine protease.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10750184
	Filing Date		2003-12-31
	First Named Inventor	Richard L. Franklin	
	Art Unit	1648	
	Examiner Name	Zachariah Lucas	
	Attorney Docket Number	ARC-1001USCON1	

	48	Von P. Billigmann, Fortschrr Med., 113(4):43-48 (1995) [German].	<input type="checkbox"/>
	49	Theodor Nasemann et al., Hautarz, 18(1):31-35 (1967) [German].	<input type="checkbox"/>
	50	V. Mazza, Folia Med., 52(9):565-578 (1969) (Napoli).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10750184
Filing Date	2003-12-31
First Named Inventor	Richard L. Franklin
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	ARC-1001USCON1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☒ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/KEVIN J. DUNLEAVY/	Date (YYYY-MM-DD)	2006-09-06
Name/Print	KEVIN J. DUNLEAVY	Registration Number	32,024

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10750184
	Filing Date		2003-12-31
	First Named Inventor	Richard L. Franklin	
	Art Unit	1648	
	Examiner Name	Zachariah Lucas	
	Attorney Docket Number	ARC-1001USCON1	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	4677069		1987-06-30	Chen et al.		
	2	4801451		1989-01-31	Hellgren et al.		
	3	4963491		1990-10-16	Hellgren et al.		
	4	5134119		1992-07-28	Lezdey John et al.		
	5	5439935		1995-08-08	Rawlings et al.		
If you wish to add additional U.S. Patent citation information please click the Add button.							Add
U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add
FOREIGN PATENT DOCUMENTS							Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10750184	
	Filing Date		2003-12-31	
	First Named Inventor	Richard L. Franklin		
	Art Unit	1648		
	Examiner Name	Zachariah Lucas		
	Attorney Docket Number	ARC-1001USCON1		

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Berenshtein, Antibiotiki, 23(11):1002-1005 (1978) [German].	<input type="checkbox"/>
	2	Daniushchenkova, Antibiotiki, 23(4):330-333 (1978) [German].	<input type="checkbox"/>
	3	C. D'Arrigo, Minerva Medica, 60(87):4327-4344 (1969) [Italian].	<input type="checkbox"/>
	4	Poul Kjer, Nordisk Medicin, 75(14):390-391 (1966).	<input type="checkbox"/>
	5	Gastshchev, Sovetskaia Meditsina, (9):52-56 (1980) [German].	<input type="checkbox"/>
	6	Gotishchev, Sovetskaia Meditsina, (5):80-83 (1978) [German].	<input type="checkbox"/>
	7	DiMarco, Clin Pediatr, (Bologna), 52(1):34-45 (1970) [Italian].	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10750184
	Filing Date		2003-12-31
	First Named Inventor	Richard L. Franklin	
	Art Unit		1648
	Examiner Name	Zachariah Lucas	
	Attorney Docket Number		ARC-1001USCON1

	8	Tokuda, Nippon Ganka Kiyo, 19(10):993-998 (1968) [Japanese].	<input type="checkbox"/>
	9	Jacobs, J Am Podiatry Assoc., 55(11):743-746 (1965) [English].	<input type="checkbox"/>
	10	Goodfriend, J Am Podiatry Assoc., 55(9):667-669 (1965) [English].	<input type="checkbox"/>
	11	Chudakov, Kirurgiia (Mosk), 49(2):87-91 (1973) [Russian].	<input type="checkbox"/>
	12	Geller, Khirurgiia (Mosk), 49(2):64-65 (1973) [Russian].	<input type="checkbox"/>
	13	Demianiuk, Klin Khir, 8:56-60 (1972) [Russian].	<input type="checkbox"/>
	14	Grigorian, Klin Khir, 9:1-4 (1971) [Russian].	<input type="checkbox"/>
	15	Bar, Lille Med., 15(5):827-847 (1970) [French].	<input type="checkbox"/>
	16	Riffat, Lyon Med., 226(13):103-106 (1971) [French].	<input type="checkbox"/>
	17	Gacon, Lyon Med., 222(43):997-1000 (1969) [French].	<input type="checkbox"/>
	18	Bazerque, Medicina (B. Aires), 32(4):357-362 (1972) [Spanish].	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10750184
Filing Date	2003-12-31
First Named Inventor	Richard L. Franklin
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	ARC-1001USCON1

19	Gordillo Fernandez, Medicina (Mex), 45(973):490-493 (1965) [Spanish].	<input type="checkbox"/>
20	Lopez Reyes, Medicina (Mex), 45(964):221-223 (1965) [Spanish].	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10750184
Filing Date	2003-12-31
First Named Inventor	Richard L. Franklin
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	ARC-1001USCON1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☒ See attached certification statement.
- ☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/KEVIN J. DUNLEAVY/	Date (YYYY-MM-DD)	2006-09-06
Name/Print	KEVIN J. DUNLEAVY	Registration Number	32,024

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.